Niche market Target institutions focused on organ failure and regenerative medicine, especially kidney-related therapies, with potential sales to research hospitals, nephrology centers, and organ transplant networks seeking advanced biomimetic platforms.

Strategic differentiator Leverage IVIVA’s fully implantable bioartificial kidney and 3D printing capabilities to position as a premium supplier of regenerative solutions, offering both therapeutic platforms and foundational organ therapeutics for collaboration with biotech and academic partners.

Funding validation Capitalize on KidneyX Phase 2 award as third-party credibility to approach government-funded programs, public health agencies, and grant-driven collaborations that may fund joint R&D and pilot deployments.

Growth traction With a revenue range of tens of millions and a small team, pursue strategic partnerships for manufacturing, scale-up, and distribution agreements to accelerate deployment while managing capital efficiency.

Talent & partnerships Engage with universities, research institutes, and potential hires in tissue engineering and stem cell biology to build a robust ecosystem; offer collaboration opportunities, joint grants, and sponsored research to expand capabilities and de-risk early-stage adoption.